Showing results (41-50 of 57) with videos related to
Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapyRichard W Joseph, Vijay R Peddareddigari, Ping Liu, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 23, 2013
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccinationLuis M Vence, Chiyu Wang, Himabindu Pappu, et al.Cancers|March 10, 2022
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor TherapyMitchell S von Itzstein, Amrit S Gonugunta, Thomas Sheffield, et al.Science Immunology|April 3, 2026
Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancerXiaoye Liu, Ryan Huang, Zhiqiang Ku, et al.Nature Metabolism|July 30, 2025
Conservation and divergence of metabolic phenotypes between patient tumours and matched xenograftsAparna D Rao, Ling Cai, Marelize Snyman, et al.Biorxiv : the Preprint Server for Biology|July 15, 2024
Cmai: Predicting Antigen-Antibody Interactions from Massive Sequencing DataBing Song, Kaiwen Wang, Saiyang Na, et al.The Lancet. Oncology|October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyNeil D Gross, David M Miller, Nikhil I Khushalani, et al.Biorxiv : the Preprint Server for Biology|December 18, 2023
pan-MHC and cross-Species Prediction of T Cell Receptor-Antigen BindingYi Han, Yuqiu Yang, Yanhua Tian, et al.Nature Cancer|June 27, 2025
Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomesBing Song, Kaiwen Wang, Saiyang Na, et al.The New England Journal of Medicine|September 12, 2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaNeil D Gross, David M Miller, Nikhil I Khushalani, et al.Pageof 6